Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.
Blinatumomab, a bispecific T-cell engager (BiTE), nearly doubled overall survival (OS) and complete remission (CR) rate vs standard chemotherapy in patients with Philadelphia chromosome (Ph)-negative relapsed/refractory B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) in the phase III TOWER trial.
A large study presented at the 21st Congress of European Haematology Association (EHA) provides further evidence for the feasibility and safety of stopping tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukaemia (CML) who have achieved a deep molecular response (MR).
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.
Men with advanced prostate cancer who have pre-existing cardiovascular disease (CVD) may have an elevated mortality risk after treatment with abiraterone acetate compared with men who do not have CVD, according to a study presented at AACR 2019.